Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?-Reference-Cited by-同舟云学术

Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?

Published:2018-10-04 Issue:1 Volume:35 Page:e3070
ISSN:1520-7552
Container-title:Diabetes/Metabolism Research and Reviews
language:en
Short-container-title:Diabetes Metab Res Rev

Author:

Gentilella Raffaella¹,Pechtner Valeria²,Corcos Antonella¹,Consoli Agostino³^ORCID

Affiliation:

1. Eli Lilly Italia; Sesto Fiorentino Italy

2. Lilly Diabetes, Eli Lilly and Company; Neuilly-sur-Seine France

3. Department of Medicine and Ageing Sciences and CeSI-Met; University D'Annunzio; Chieti Italy

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/dmrr.3070/fullpdf

Reference148 articles.

1. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes;Inzucchi;Diabetes Care,2015

2. Garber AJ , Abrahamson MJ , Barzilay JI , et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2018 executive summary . https://www.aace.com/sites/all/files/diabetes-algorithm-executive-summary.pdf . Accessed May 14, 2018 .

3. AstraZeneca . Byetta (exenatide) European summary of product characteristics . Updated 21 February 2018 . http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000698/WC500051845.pdf . Accessed June 14, 2018 .

4. AstraZeneca AB . Bydureon (exenatide extended release) European summary of product characteristics . Updated 19 January 2018 . http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002020/WC500108241.pdf . Accessed June 14, 2018 .

5. Sanofi-Aventis . Lyxumia (lixisenatide) European summary of product characteristics . Updated 4 October 2017 . http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002445/WC500140401.pdf . Accessed June 14, 2018 .

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin‐4‐IgG4‐Fc in healthy subjects: A phase 1, single‐centre, randomized, double‐blind, dose escalation study;Diabetes, Obesity and Metabolism;2024-01-29

2. Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks;Alimentary Pharmacology & Therapeutics;2024-01-02

3. Peptide and protein delivery through cellulose, hyaluronic acid, and heparin;Peptide and Protein Drug Delivery Using Polysaccharides;2024

4. Advantages of glucagon-like peptide agonists in the light of prevention of cardiovascular and renal complications;FOCUS. Endocrinology;2023-12-27

5. Exendin‐4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease;Chemical Biology & Drug Design;2023-12-15